The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Zamtocabtagene autoleucel (MB-CART2019.1): a novel CAR-T approach in R/R B-NHL
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses a Phase I study (NCT03870945) aiming to evaluate the efficacy and safety of zamtocabtagene autoleucel (MB-CART2019.1), a novel CAR-T product, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). This line of treatment was found to have an encouraging safety profile, as no dose-limiting toxicities and very few treatment-emergent adverse events (TEAEs) were reported. Robust and durable CAR-T expansion was seen in the study cohort, with some patients achieving complete remission. Phase II and III studies investigating zamtocabtagene autoleucel are currently underway. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
